Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Lohse I, Azzam DJ, Al-Ali H, Volmar C-, Brothers SP, Ince TA, et al. Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing. Anticancer Res. 2019;39(8):4023-4030.

Davuluri M, Long B, Semple S, Villanueva-Siles E, Aboumohamed A. Primary Urethral Melanoma: A Case Report and Literature Review. Urology. 2019;126:1-4.

Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.

Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Diagn Cytopathol. 2019;47(10):977-985.

Gross MD, Awamlh BA, Shoag JE, Mauer E, Banerjee S, Margolis DJ, et al. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions. BMJ Surg Interv Health Technol. 2019;1(1):e000010.

Armenia J, Wankowicz SA, Liu D, Gao J, Kundra R, Reznik E, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2019;51(7):1194.

Farber G, Parks MM, Guahmich NL, Zhang Y, Monette S, Blanchard SC, et al. ADAM10 controls the differentiation of the coronary arterial endothelium. Angiogenesis. 2019;22(2):237-250.

Starza ID, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838-2840.